Circulating Tumor Cells and Early Relapse in Node-positive Melanoma
- 1 April 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (8), 1886-1895
- https://doi.org/10.1158/1078-0432.CCR-19-2670
Abstract
Purpose: There is a need for sensitive, reproducible biomarkers for patients with stage III melanoma to guide clinical decision making. Circulating tumor cells (CTCs) can be detected in patients with melanoma; however, there are limited data regarding their significance in stage III disease. The aim of this study was to determine whether CTCs are associated with early relapse in stage III melanoma. Experimental Design: We prospectively assessed CTCs at first presentation in clinic (baseline) for 243 patients with stage III melanoma. CTCs were measured using the CellSearch System. Relapse-free survival (RFS) was compared between patients with one or more baseline CTC versus those with no CTCs. Log-rank test and Cox regression analysis were applied to establish associations of CTCs with RFS. Results: At least one baseline CTC was identified in 90 of 243 (37%) patients. Forty-five (19%), 67 (28%), 118 (49%), and 13 (5%) patients were stage IIIA, IIIB, IIIC, or IIID, respectively. CTC detection was not associated with substage, or primary tumor characteristics. Multivariable analysis demonstrated that the detection of >= 1 baseline CTC was significantly associated with decreased 6-month RFS [log-rank, P < 0.0001; HR, 3.62, 95% confidence interval (CI), 1.78-7.36; P < 0.0001] and 54-month RFS (log-rank, P = 0.01; HR, 1.69; 95% CI, 1.13-2.54; P = 0.01). Conclusions: >= 1 CTC was independently associated with melanoma relapse, suggesting that CTC assessment may be useful to identify patients at risk for relapse who could derive benefit from adjuvant therapy.Other Versions
Funding Information
- The Wintermann Foundation
This publication has 29 references indexed in Scilit:
- Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in MelanomaThe New England Journal of Medicine, 2014
- Circulating melanoma cells and survival in metastatic melanomaInternational Journal of Oncology, 2011
- Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic MelanomaClinical Cancer Research, 2010
- A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human MelanomasCancer Research, 2010
- Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a markerJournal of Molecular Medicine, 2010
- Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)European Journal of Cancer, 2009
- Circulating Tumor Cell as a Diagnostic Marker in Primary Lung CancerClinical Cancer Research, 2009
- Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanomaMelanoma Research, 2007
- Prospective Multi-Institutional Study of Reverse Transcriptase Polymerase Chain Reaction for Molecular Staging of MelanomaJournal of Clinical Oncology, 2006
- Peripheral Blood Tyrosinase Messenger RNA Detection and Survival in Malignant MelanomaJNCI Journal of the National Cancer Institute, 1996